Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to
explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of
NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that
are expected to provide meaningful clinical benefit or for whom standard therapy is
considered unsuitable.